中国临床康复
中國臨床康複
중국림상강복
CHINESE JOURNAL OF CLINICAL REHABILITATION
2004年
5期
984-985
,共2页
李海刚%董书堃%曾韵洁%沈溪明%曾弘%任明能
李海剛%董書堃%曾韻潔%瀋溪明%曾弘%任明能
리해강%동서곤%증운길%침계명%증홍%임명능
骨肿瘤%纤溶酶原激活剂%原位杂交
骨腫瘤%纖溶酶原激活劑%原位雜交
골종류%섬용매원격활제%원위잡교
目的:研究骨巨细胞瘤(giant celltumor of bone,GCT)组织尿激酶型纤溶酶原激活剂(urokinase-type plasminogen activator,u-PA)系统mRNA的表达与GCT病理分级和复发的关系.方法:用原位杂交技术检测42例GCT组织u-PA,u-PA受体(u-PAR)及其抑制因子2(PAI-2)mRNA的表达.结果:①u-PA,u-PAR,PAI-2 mRNA在GCT组织多核巨细胞(MGC)的阳性率分别为64.3%,71.4%和40.5%;单核基质细胞(MC)的阳性率分别为54.8%,45.2%和9 5%.②Ⅱ、Ⅲ级和复发组GCT的MGCu-PA mRNA与MC u-PA,u-PAR mRNA的表达率均明显高于Ⅰ级(x2分别为8.00,7.82,6.81,P<0.05)和无复发组(x2分别为5.49,5.54,9.84,P<0.05);③GCT组织两种细胞间的u-PA mRNA表达(P<0.05)、MGC u-PAR与PAI-2 mRNA的表达间、MC u-PA与u-PAR mRNA的表达间均呈正相关(x2分别为7.20,8.19,P<0.05);MGC PAI-2 mRNA的阳性率明显高于MC的阳性率(x2=10.73,P<0.05).结论:GCT组织u-PA,u-PAR mRNA的表达,尤其是在MC中的表达,与骨巨细胞瘤恶性程度密切相关.
目的:研究骨巨細胞瘤(giant celltumor of bone,GCT)組織尿激酶型纖溶酶原激活劑(urokinase-type plasminogen activator,u-PA)繫統mRNA的錶達與GCT病理分級和複髮的關繫.方法:用原位雜交技術檢測42例GCT組織u-PA,u-PA受體(u-PAR)及其抑製因子2(PAI-2)mRNA的錶達.結果:①u-PA,u-PAR,PAI-2 mRNA在GCT組織多覈巨細胞(MGC)的暘性率分彆為64.3%,71.4%和40.5%;單覈基質細胞(MC)的暘性率分彆為54.8%,45.2%和9 5%.②Ⅱ、Ⅲ級和複髮組GCT的MGCu-PA mRNA與MC u-PA,u-PAR mRNA的錶達率均明顯高于Ⅰ級(x2分彆為8.00,7.82,6.81,P<0.05)和無複髮組(x2分彆為5.49,5.54,9.84,P<0.05);③GCT組織兩種細胞間的u-PA mRNA錶達(P<0.05)、MGC u-PAR與PAI-2 mRNA的錶達間、MC u-PA與u-PAR mRNA的錶達間均呈正相關(x2分彆為7.20,8.19,P<0.05);MGC PAI-2 mRNA的暘性率明顯高于MC的暘性率(x2=10.73,P<0.05).結論:GCT組織u-PA,u-PAR mRNA的錶達,尤其是在MC中的錶達,與骨巨細胞瘤噁性程度密切相關.
목적:연구골거세포류(giant celltumor of bone,GCT)조직뇨격매형섬용매원격활제(urokinase-type plasminogen activator,u-PA)계통mRNA적표체여GCT병리분급화복발적관계.방법:용원위잡교기술검측42례GCT조직u-PA,u-PA수체(u-PAR)급기억제인자2(PAI-2)mRNA적표체.결과:①u-PA,u-PAR,PAI-2 mRNA재GCT조직다핵거세포(MGC)적양성솔분별위64.3%,71.4%화40.5%;단핵기질세포(MC)적양성솔분별위54.8%,45.2%화9 5%.②Ⅱ、Ⅲ급화복발조GCT적MGCu-PA mRNA여MC u-PA,u-PAR mRNA적표체솔균명현고우Ⅰ급(x2분별위8.00,7.82,6.81,P<0.05)화무복발조(x2분별위5.49,5.54,9.84,P<0.05);③GCT조직량충세포간적u-PA mRNA표체(P<0.05)、MGC u-PAR여PAI-2 mRNA적표체간、MC u-PA여u-PAR mRNA적표체간균정정상관(x2분별위7.20,8.19,P<0.05);MGC PAI-2 mRNA적양성솔명현고우MC적양성솔(x2=10.73,P<0.05).결론:GCT조직u-PA,u-PAR mRNA적표체,우기시재MC중적표체,여골거세포류악성정도밀절상관.
AIM: To investigate the relationship between the expression of uroki- nase-type plasminogen activator(u-PA) mRNA in giant cell tumors of bone(GCT) and pathological grading and recurrence of GCT.METHODS: The expressions of u-PA, u-PA receptor(u-PAR) and u-PA inhibitors(PAI) -2 mRNA in the specimens of GCT obtained by surgical curettement from 42 cases, 13 of grade Ⅰ, 23 of grade Ⅱ, and 6 of grade Ⅲ,and 12 relapsing 5 -32 months later, were detected with in situ hybridization (ISH).RESULTS: ① The expression rates of u-PA, u-PAR, and PAI-2 mRNA in the multinuclear giant cells(MGCs) in the GCT tissues were 64.3%,71.4% and 40.5% respectively, and the expression rates in the mononuclear cells(MCs) were 54.8% , 45.2% and 9.5% respectively. ② The expression rate of u-PA mRNA in MGC, and the expression rates of u-PA and u-PAR mRNAs in MC were significantly higher in the cases of grade Ⅱ and Ⅲ than in the cases of grade I (X2 = 8.00, 7.82, and 6.81, all P <0. 05) and significantly higher in the non-recurrent group (X2 = 5.49, 5.54,and 9.84, P<0.05). ③ A closely positive relationship was shown between the expression of u-PA mRNA in MGC and in MC ( P < 0. 05 ), between the expression of u-PAR and of PAI-2 mRNA in MGC (x2 = 7.20, P < 0. 05),and between the expression of u-PA and expression of u-PAR mRNA in MC (X2 =8.19, P <0.05) . The expression rate of PAI-2 mRNA in MGC was higher than that in MC significantly (x2 = 10. 73, P < 0. 05).CONCLUSION: The expressions of u-PA and u-PAR mRNA in GCT tissues, especially in MC, are closely related to the malignancy of GCT.